Problem

Raycaster addresses the document bottleneck in high-stakes work, initially drug development. In life sciences, critical information is spread across protocols, batch records, specifications, laboratory reports, clinical data, regulatory modules, and prior submissions. Teams often copy and reconcile material across PDFs and Word files, creating version sprawl, manual rework, and opportunities for inconsistencies. The stakes are unusually high: delays and mistakes in clinical, CMC, quality, and regulatory documents can slow drug-development timelines and become extremely expensive.

The killer use case is project-level dossier work rather than drafting an isolated document. For example, a team may need to update a batch formula, cover letter, and justification after a scale-up while preserving cross-references across a large submission. Raycaster targets this kind of coordinated drafting, editing, and review across thousand-page dossiers, where a single source of truth and reliable traceability can replace dozens of disconnected document versions.

Product / Service

Raycaster is an AI-native document workspace, initially positioned as “Cursor for Documents” for regulated life-sciences content. Teams bring source material such as guidance, prior submissions, lab reports, certificates of analysis, batch records, Word files, PDFs, spreadsheets, and presentations into a workspace. The system represents dependencies among those files, then uses an AI agent to research, draft, edit, and reconcile work across the project while preserving citations and review controls.

The product is designed for controlled changes rather than opaque text generation. It can propose precise, diff-aware edits, show red-and-green changes, and explain why each change was made. Raycaster’s broader workflow is built around cited findings, human review, and evaluation of finished artifacts, so teams can inspect what the system did, decide whether it is acceptable, and improve it over time. The company now presents the same model for other high-stakes workflows, including contract review, diligence, energy packages, and regulated dossiers.

Market

Raycaster competes in AI-native document workspaces, regulated-content management, and life-sciences regulatory and CMC software. Its initial beachhead is biopharma teams working on CMC, quality, clinical, and regulatory documents, while its current positioning extends to other document-heavy workflows. The competitive set includes established platforms such as Veeva’s Vault ecosystem and Generis in life-sciences content and regulatory management, specialized products such as Celegence’s AI-powered CMC writing tools, and the broader workflow concept popularized by Cursor. Raycaster’s differentiation is the combination of project-level agentic editing, cross-document reconciliation, citations, human review, and measurable evaluation rather than simple chat or standalone authoring.

Public evidence indicates early commercial traction rather than a pre-revenue product. Raycaster is listed as an active Fall 2024 Y Combinator company, and a company hiring post says it is already working with enterprise customers globally while hiring its first GTM employee to turn early demand into a repeatable sales process. Third-party databases report approximately $500,000 raised and estimate $880,000 of 2025 revenue or ARR, although those financial figures are not company-reported in the available evidence and should be treated as indicative rather than verified.